MMJ BioPharma’s noble pursuit of scientific advancement has been met with a series of inexplicable roadblocks and bureaucratic hurdles erected by the DEA. In 2018, the company dutifully applied for the necessary licenses to cultivate marijuana for research and development purposes, eagerly anticipating the opportunity to commence clinical trials that could yield life-changing treatments. Yet, despite meticulously following the DEA’s convoluted application process, MMJ BioPharma found itself trapped in a seemingly endless cycle of delays, obfuscation, and stonewalling.
Save dough on the good-good without breaking a sweat. The post Why you should shop…
Quantity vs. Frequency - One of the most significant distinctions between medical and recreational cannabis…
At least 10 states and Amsterdam have new stores for you. The post Grand Openings:…
Welcome all Stargazers! November promises a month of celestial buoyancy even as the days and…
According to fresh data from the US National Institute on Drug Abuse, young women have…
Many states have enacted strict privacy laws that prevent dispensaries from sharing customer data without…